NewcelX closed at $2.56 on Nov 4, down 3.03%, 54.7% below its 52-week closing high. Volume of 282.7K shares was 31.34× its 20-day average (well above normal).
Split-adjusted performance: -13.5% over one month, -22.9% over six months, -50.2% over one year.
Short interest was 9.8K shares at the Oct 15 settlement (0.4% of float, 2.1 days to cover).
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement.
What is NCEL's market cap?
$14.79M, based on the Nov 4 close of $2.56.
Does NewcelX pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NCEL is sold short?
9.8K shares, 0.4% of float, as of Oct 15, 2026.
About NewcelX
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
